Worldwide Hematology Testing Industry to 2027 - by Product, Test Type, End-user and Geography
December 22, 2021 05:18 ET
|
Research and Markets
Dublin, Dec. 22, 2021 (GLOBE NEWSWIRE) -- The "Hematology Testing Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. In-depth Analysis and...
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
December 13, 2021 07:00 ET
|
Imara, Inc.
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease
November 22, 2021 07:00 ET
|
Imara, Inc.
Primary endpoint to be changed to annualized rate of VOCs following written U.S. Food and Drug Administration recommendation No change to conduct or size of trial planned; Ardent trial remains on...
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
November 04, 2021 09:17 ET
|
Imara, Inc.
Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented Oral presentation...
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
August 06, 2021 07:00 ET
|
Imara, Inc.
Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021 Positive IMR-687 data in sickle cell disease presented at...
Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
August 05, 2021 07:15 ET
|
Imara, Inc.
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces Pricing of Public Offering
July 13, 2021 22:58 ET
|
Imara, Inc.
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...
Imara Announces Launch of Proposed Public Offering
July 13, 2021 16:01 ET
|
Imara, Inc.
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...
Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors
June 30, 2021 07:00 ET
|
Imara, Inc.
BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 11, 2021 03:00 ET
|
Imara, Inc.
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial...